Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Solomon, Benjamin; Dagogo‐Jack, Ibiayi; Lee, Se-Hoon; Boyer, Michael; S. Ramalingam, Suresh; Carcereny, Enric; Felip, Enriqueta; Han, Ji‐Youn; Hida, Toyoaki; Hughes, Brett; Kim, Sang‐We; Nishio, Makoto; Seto, Takashi; Okamoto, Tatsuro; Zhang, Xiaoxi; Martini, Jean‐François; Wang, Erjian; De Beukelaer, Steven; M. Bauer, Todd

doi:10.1016/j.jtocrr.2024.100685

Public

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Published in JTO Clinical and Research Reports • May 16, 2024

Authors:

Benjamin Solomon

Ibiayi Dagogo‐Jack

Se-Hoon Lee

Abstract

Introduction The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK -positive or ALK -negative advanced NSCLC, respectively. Methods Starting doses of lorlatinib 100 mg once daily or crizotinib...

Subject

Crizotinib

Javelin

Avelumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!